AtonRa Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

AtonRa Partners’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$510K	Sell	2,662 -273	-9%	-$46.5K	1.02%	34
2023 Q3	$520K	Sell	2,935 -675	-19%	-$129K	1.09%	24
2023 Q2	$686K	Sell	3,610 -158	-4%	-$31.3K	1.06%	26
2023 Q1	$755K	Sell	3,768 -485	-11%	-$102K	1.1%	27
2022 Q4	$1.01M	Sell	4,253 -1,776	-29%	-$379K	1.29%	22
2022 Q3	$1.21M	Sell	6,029 -43	-0.7%	-$8.2K	1.19%	23
2022 Q2	$886K	Sell	6,072 -3,509	-37%	-$498K	0.81%	49
2022 Q1	$1.56M	Buy	9,581 +149	+2%	+$22.7K	0.85%	48
2021 Q4	$1.6M	Buy	9,432 +748	+9%	+$139K	0.56%	64
2021 Q3	$1.64M	Buy	8,684 +587	+7%	+$110K	0.55%	75
2021 Q2	$1.37M	Sell	8,097 -12,113	-60%	-$1.77M	0.5%	72
2021 Q1	$2.85M	Buy	20,210 +12,820	+173%	+$1.93M	1.27%	25
2020 Q4	$960K	Buy	+7,390	New	+$987K	0.47%	68

Other funds holding ALNY

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

AtonRa Partners's ALNY Position: Q4 2023 in Review

AtonRa Partners reduced its Alnylam Pharmaceuticals (ALNY) stake by 9.3% in Q4 2023, selling an estimated $46.5K and leaving 2,662 shares worth $510K. The position accounts for 1.02% of the portfolio, ranked #34.

AtonRa Partners first reported a position in ALNY in Q4 2020 and has held it in 13 quarters since. The position peaked at $2.85M in Q1 2021. 498 funds tracked by Wall St. Rank hold ALNY as of Q4 2023.

AtonRa Partners held 2,662 shares of Alnylam Pharmaceuticals worth $510K as of Q4 2023.
AtonRa Partners sold 273 Alnylam Pharmaceuticals shares in Q4 2023, an estimated $46.5K.
Alnylam Pharmaceuticals made up 1.02% of AtonRa Partners's portfolio in Q4 2023, its #34 holding.
AtonRa Partners first reported a position in Alnylam Pharmaceuticals in Q4 2020 and has held it in 13 quarters since.
AtonRa Partners's Alnylam Pharmaceuticals position peaked at $2.85M in Q1 2021.
498 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2023.

Based on AtonRa Partners's 13F filing for Q4 2023, filed 5 Feb 2024.